A groundbreaking first-in-human study presented at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting is exploring whether transplanted insulin-producing cells can survive and function in type 1 diabetes patients without requiring lifelong immunosuppression. The research addresses one of the biggest obstacles preventing cell replacement therapy from becoming a mainstream treatment: the body's immune system attacking and rejecting transplanted cells.

What Makes This Type 1 Diabetes Study Different?

Currently, type 1 diabetes is managed by replacing insulin through injections or pumps, not by replacing the insulin-producing cells that the immune system has destroyed. This new approach uses "hypoimmune engineering," a technique that modifies transplanted cells to hide from the immune system, allowing them to persist and function without the patient needing to take immunosuppressive medications for the rest of their life.

The central challenge the research tackles is immune rejection. When doctors transplant insulin-producing cells from a donor into a patient, the recipient's immune system recognizes them as foreign and attacks them. Previous cell replacement therapies have required patients to take powerful immunosuppressive drugs continuously, which carry their own health risks and complications. This new study investigates whether hypoimmune engineering can change that equation.

"Type 1 diabetes is still treated primarily by replacing insulin, not by replacing the insulin-producing cells that were lost. Our goal is to develop a cell replacement approach that can survive and function without chronic immunosuppression, with the long-term vision of providing a curative therapy for people with type 1 diabetes," said Sonja Schrepfer, M.D., Ph.D., at Cedars-Sinai Medical Center.

Sonja Schrepfer, M.D., Ph.D., Cedars-Sinai Medical Center

How Could This Approach Transform Type 1 Diabetes Treatment?

• Elimination of Chronic Medications: If successful, patients would no longer need to take immunosuppressive drugs daily, reducing medication burden and associated side effects that can affect kidney function, bone health, and infection risk.
• Restoration of Natural Insulin Production: Rather than managing blood sugar through external insulin delivery, the transplanted cells would produce insulin naturally in response to blood glucose levels, mimicking how a healthy pancreas works.
• Reduced Daily Disease Management: Patients would no longer need to count carbohydrates, calculate insulin doses, or monitor blood glucose as intensively, significantly improving quality of life and reducing the psychological burden of constant diabetes management.

The implications extend beyond type 1 diabetes alone. If immune-engineered cells can be safely protected from rejection, the same approach could eventually enable "off-the-shelf" cell, tissue, and organ transplants that could be made available to patients whenever and wherever they are needed, rather than requiring a perfect donor match.

"What is most meaningful is that we are now able to ask, in a human study, whether hypoimmune engineering can allow transplanted allogeneic cells to persist and function without chronic immunosuppression. That has been a central question for the field," explained Dr. Schrepfer.

Sonja Schrepfer, M.D., Ph.D., Cedars-Sinai Medical Center

What Questions Still Need Answers?

While the research represents a significant milestone, important questions remain before this approach becomes widely available. Researchers need to understand how long the therapy will last, whether the immune-engineered cells can withstand both the body's general immune response and the specific autoimmune attack that originally destroyed the patient's own insulin-producing cells, and how to scale the approach into affordable, accessible treatments for larger patient populations.

The study also opens doors for future research into whether this immune-engineering strategy could work for other cell and tissue transplants, potentially revolutionizing how doctors treat conditions that require cell replacement. For type 1 diabetes specifically, success in this trial could represent a major step toward what researchers call a "functional cure," where patients regain biological insulin production and experience dramatically reduced daily disease burden.

"If we can reliably protect transplanted cells from immune rejection, this approach could open the door to many types of off-the-shelf cell, tissue, and eventually organ replacement therapies that can be available to patients when and where they are needed," Dr. Schrepfer noted.

Sonja Schrepfer, M.D., Ph.D., Cedars-Sinai Medical Center

For the millions of people living with type 1 diabetes, this research represents a fundamental shift in how the disease might be treated. Rather than managing a chronic condition through daily insulin injections and constant monitoring, patients could potentially receive a one-time cell transplant that restores their body's natural ability to produce insulin. While the research is still in early human testing, the results could reshape type 1 diabetes care within the next decade.